A phase 2/3 multicenter, randomized, double blind study of docetaxel (Taxotere) plus DN-101 [calcitriol] or placebo in androgen independent prostate cancer
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Calcitriol (Primary) ; Docetaxel (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Acronyms ASCENT
- 20 Feb 2007 Results have been published.
- 20 Feb 2007 Status change
- 27 Sep 2005 New trial record.